theMednetRegister

Endocrinology

Lipid Disorders   

Questions discussed in this category

For a patient with known CAD and low baseline HDL, would a PCSK9 inhibitor be a better option than a statin, given concerns for paradoxical lowering of HDL levels with statin therapy that we can encounter in the outpatient clinical setting? 
4 Answers available
In ischemic stroke patients with low LDL levels (<30-50 mg/dl), would you consider lowering LDL levels to lower values without concern for any side effects?
How would you adjust statin therapy in these patients?
4 Answers available
Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?
Ferrell et al., PMID 38448791
6 Answers available
How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long term CVD risk?
1 Answer available
Will TRYNGOLZA (olezarsen), recently approved for familial chylomicronemia syndrome, also lower triglycerides due to other genetic causes of hypertriglyceridemia?
2 Answers available
Is moderate-intensity statin plus ezetimibe just as effective as high-intensity statin monotherapy in preventing major cardiovascular events?
4 Answers available
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
1 Answer available
When do you recommend plasmapheresis/plasma exchange for management of severe hypertriglyceridemia?
2 Answers available
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
1 Answer available
Should all kidney transplant patients be started on statin therapy post operatively given their increased risk of CVD?
At what doses do you start? and how do you titrate therapy?
1 Answer available
Do you recommend the use of bempedoic acid (Nexletol) for treatment of hyperlipidemia in patients with elevated baseline uric acid levels?
Should uric acid levels be monitored regularly while on therapy?
1 Answer available
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
Cholesterol Treatment Trialists' (CTT) Collaboration
2 Answers available
For patients with metabolic syndrome, is it reasonable to wait for the effect of tirzepatide therapy on their lipid profile prior to starting statin therapy?
4 Answers available
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
1 Answer available
What are the indications for use of inclisiran over anti-PCSK9 monoclonal antibody therapies?
2 Answers available
Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?
3 Answers available
What are the clinical indications and major limitations of lipoprotein apheresis?
2 Answers available
When and for whom should we consider adding bempedoic acid to the lipid lowering regimen?
3 Answers available
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
1 Answer available
Should Orlistat be considered in the management of hypertriglyceridemia?
1 Answer available
Would you treat an isolated elevated total cholesterol in a post-menopausal patient who is otherwise healthy and has no significant CV risk factors?
2 Answers available
Should patients with mild subclinical hypothyroidism (TSH < 10 mIU/L) be treated with thyroid hormone replacement to improve their lipid profile?
2 Answers available
Should lipid lowering therapy be started in patients with isolated elevation in lipoprotein (a) and minimal cardiovascular risk?
2 Answers available
Should insulin be started early (prior to optimization of other anti-hyperglycemic medications) in patients with mild-to-moderate diabetes and hypertriglyceridemia refractory to statin and fibrates?
2 Answers available


Papers discussed in this category

Journal of the American Heart Association, 2015 Jun 26
Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Mayo Clinic proceedings, 2023 Jun 29
Progression to Insulin Therapy in Patients With Type 2 Diabetes According to Cardiorespiratory Fitness, Body Mass Index, and Statin Therapy.
The Journal of clinical endocrinology and metabolism, 2011 Dec 28
Update in lipid alterations in subclinical hypothyroidism.
Curr Rheumatol Rep, 2020 Aug 26
Lipid-lowering Therapies in Myositis.
The American journal of cardiology, 2004-02-01
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
Nature medicine, 2024 Feb 19
A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.
Journal of clinical lipidology, 2024 Mar 29
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.
Journal of the American College of Cardiology, 1986-12
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
The New England journal of medicine, 2011-12-15
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
Current opinion in lipidology, 2007 Aug
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.
The American journal of cardiology, 2005 Jun 01
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
Trials, 2018 Mar 05
Improved adherence adjustment in the Coronary Drug Project.
The New England journal of medicine, 2014 Jul 17
Effects of extended-release niacin with laropiprant in high-risk patients.
JAMA, 1975 Jan 27
Clofibrate and niacin in coronary heart disease.
N Engl J Med,
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Autoimmunity reviews, 2023 Dec 20
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.
Stroke, 2007-12
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
The New England journal of medicine, 2006 Aug 10
High-dose atorvastatin after stroke or transient ischemic attack.
European heart journal, 2020 Jan 01
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Journal of the American Heart Association, 2023 Sep 08
Statin Treatment in Patients With Stroke With Low-Density Lipoprotein Cholesterol Levels Below 70 mg/dL.
The New England journal of medicine, 2011-12-01
Effect of two intensive statin regimens on progression of coronary disease.
Circulation, 2019-06-18
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
The New England journal of medicine, 2024 Apr 07
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
Journal of clinical lipidology, 2022 Sep 11
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association.

Related Topics in Endocrinology

Copyright © 2025 theMednet
All Rights Reserved.